

Lancashire and South Cumbria Clinical Commissioning Groups Commissioning Policy Reviews

Otitis Media with Effusion (OME) using Grommets Public Engagement Outcomes			
When the public engagement took place	Start date	End date	Duration
	09 July 2018	03 August 2018	4 weeks
Number of survey respondents – electronic or on paper	Total	By gender	By disability
	8	Female: 63% Male: 37%	No disability: 75% Disability: 25%
	By sexual orientation	By ethnicity	
	Heterosexual: 100% Gay/Lesbian: 0% Bisexual: 0%	White British: 87% Asian ethnicity: 13% Other: 0%	Mixed ethnicity: 0% Black ethnicity: 0%
Number of people seen face-to-face	Not applicable		
	0		
Survey question response rates from patients and members of the public	100% of respondents read the OME using grommets policy before completing the survey	63% of those who responded felt it should only be funded for those people who meet the criteria	38% of survey respondents had received this treatment/procedure
	87% of survey respondents agreed with the criteria for otitis media with effusion using grommets and 13% disagreed with the criteria		
Key issues/themes raised by patients and members of the public	The procedure should be available to children regardless of whether they have underlying conditions/additional disabilities		
	Greater support is needed for parents of children with OME		
	Concern there is a lack of funding from the CCG to support children with OME		
Responses to key issues/themes raised during public engagement	The risk of a surgical procedure ought to be less than the risk of not intervening. Research has demonstrated that this risk is best managed by following the criteria identified		
	Supporting parents and the child is important but is outside the scope of this policy development		
	The funding for OME has not been altered and is required to treat all children under 12 who meet the criteria		

Key changes to the policy following public engagement (if applicable)

Not applicable – no changes made to the policy as a result of the feedback received

Policy ratified by Joint Committee of Clinical Commissioning Groups on 5 October 2018